

Xeomin® (incobotulinumtoxinA)

When requesting Xeomin® (incobotulinumtoxinA), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines for the covered indications.

FDA-Approved Indications

Xeomin (incobotulinumtoxinA) is indicated for the treatment of adults with:

- Upper limb spasticity
- Cervical dystonia
- Blepharospasm
- Chronic sialorrhea

Coverage Guidelines

The individual must be 18 years of age or older for approval of the following indications:

- Upper limb spasticity
- Cervical dystonia
- Blepharospasm
- Chronic sialorrhea

Approval duration: 12 months

Dosing Recommendations

Blepharospasm

Approve up to a maximum dose of 100 units (50 units per eye), administered not more frequently than once every 12 weeks.

Cervical Dystonia

Approve up to a maximum dose of 120 units, administered not more frequently than once every 12 weeks.

Upper Limb Spasticity

Approve up to a maximum dose of 400 units, administered not more frequently than once every 12 weeks.

Chronic Sialorrhea

Approve up to a maximum dose of 100 units (50 units per side), administered not more frequently than once every 16 weeks.

References

1. Xeomin® (incobotulinumtoxinA) [prescribing information]. Raleigh, NC: Merz Pharmaceuticals, LLC: May 2019;
2. Xeomin® (incobotulinumtoxinA). IN: DRUGDEX System Micromedex. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Updated May 20, 2019; Accessed July 1, 2019].
3. Simpson, D et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *American Academy of Neurology* (2016) 86: 1818-1826.